AR and prostate cancer: Employing an orally bioavailable p300/CBP PROTAC degrader, CBPD-409, with excellent selectivity and potency, we demonstrate that specific degradation of p300/CBP can achieve superior suppression of AR-positive prostate cancer cell growth relative to p300/CBP bromodomain inhibitors and HAT domain inhibitors.